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Abstract 
 
Low 25-hydroxyvitamin D levels are associated with higher prevalent blood pressure. We 
tested whether high-dose intermittent oral vitamin D therapy could reduce blood pressure and 
left ventricular mass in patients with hypertension resistant to conventional treatment. We 
conducted a parallel-group, double-blind, randomised placebo-controlled trial. Patients with 
supine office blood pressure >140/90 mmHg on 3 or more antihypertensive agents received 
100,000 units oral vitamin D3 or matching placebo every 2 months. Office and 24 hour 
ambulatory blood pressure, glucose and cholesterol were measured at baseline, 2,4 and 6 
months; left ventricular mass index was measured by cardiac magnetic resonance imaging on 
a subgroup at baseline and 6 months. The primary outcome was mean 24 hour ambulatory 
blood pressure at 6 months. 68 participants were randomised, 34 to each group. Mean age 
was 63 (SD 11)  years, mean baseline office blood pressure was 154/84 (13/10) mmHg and 
mean baseline 25-hydroxyvitamin D level was 42(16) nmol/L. Treatment with vitamin D did 
not reduce 24 hour ambulatory blood pressure (adjusted treatment effects: systolic +3mmHg, 
95%CI -4 to +11, p=0.33; diastolic -2mmHg, 95%CI -6 to +2, p=0.29); similar results were 
seen for office blood pressure. Left ventricular mass index was measured in a subgroup 
(n=25); no reduction was seen with vitamin D treatment (adjusted treatment effect +4g/m2, 
95%CI 0 to +7, p=0.04). There was no significant change in cholesterol or glucose levels. 
Thus six months of intermittent, high-dose oral vitamin D3 did not reduce blood pressure or 
left ventricular mass in patients with resistant hypertension. 
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Introduction 
Resistant hypertension, defined as an office systolic blood pressure of >140mmHg or 
diastolic blood pressure of >90mmHg despite maximally tolerated treatment with three or 
more antihypertensive agents, affects 10 to 30% of patients with hypertension1. Resistance to 
treatment is associated with a high incidence of cardiovascular events2. Resistant 
hypertension is also associated with a high incidence of left ventricular hypertrophy3, itself a 
risk factor for cardiovascular events, arrhythmias and death4. 
 
Relatively few studies target resistant hypertensive patients as a discrete subgroup, and 
treatment algorithms are not as well defined for this group of patients as for those with more 
straightforward mild to moderate hypertension. Despite a wide range of antihypertensive 
agents now being available with multiple modes of action, treatment of resistant hypertension 
remains problematic, with many patients suffering from treatment-limiting side-effects5. 
Although recent interest has focussed on invasive solutions such as renal denervation 
therapy6, the large burden of resistant hypertension at the population level means that 
inexpensive, easily applied interventions to mitigate the problem are still required. 
 
Low vitamin D levels are associated with higher blood pressure7 and a higher rate of both 
incident hypertension8 and cardiovascular disease9;10 in observational studies. Previous 
intervention trials11 have suggested that vitamin D may reduce blood pressure in selected 
groups of patients with hypertension; however no trials to date have evaluated the effects of 
vitamin D on resistant hypertension. Pathophysiological investigation suggests a link between 
low vitamin D levels and left ventricular hypertrophy, possibly mediated by parathyroid 
hormone12;13, but very few studies have examined the effect of vitamin D analogues on left 
ventricular mass14;15. We therefore conducted a randomised controlled trial to test the effect 
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of intermittent high-dose vitamin D on 24 hour ambulatory blood pressure and left ventricular 
mass in patients with resistant hypertension. 
 
Methods 
Design and Participants 
We performed a randomised, double-blind, placebo controlled, parallel group trial. 
Participants were recruited via cardiovascular medicine clinics and via primary care services 
in Tayside, Scotland. Participants were eligible for inclusion if they were aged 18 or over, 
had a supine office blood pressure of >140/90 mmHg, were on 3 or more antihypertensive 
medications (resistant hypertension), and had serum 25-hydroxyvitamin D (25OHD) levels 
<75nmol/L. 
 
Participants were excluded if they had hypertension known to be due to a correctable 
underlying surgical or medical cause, had albumin-adjusted calcium levels of >2.60 mmol/L 
or <2.15 mmol/L, sarcoidosis, history of renal stones, or a previous clinical diagnosis of 
osteomalacia. Other exclusion criteria were liver function tests >3x upper limit of normal, 
estimated glomerular filtration rate by the Modified Diet in Renal Disease four variable 
equation of <40ml/min, metastatic malignancy, heart failure with left ventricular systolic 
dysfunction or known atrial fibrillation. Participants were excluded if already taking 
pharmacological vitamin D preparations (fish oils were permitted), were unable to give 
written informed consent, were pregnant, lactating, or were women of childbearing age 
without taking reliable contraception. Participants with contraindications to magnetic 
resonance imaging (MRI) scanning were permitted to enter the main study but were excluded 
from the MRI substudy. Written informed consent was obtained from all participants; ethical 
approval was given by Tayside Research Ethics committee (ref: 08/S1402/31). Clinical trials 
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authorisation was obtained from the UK Medicines and Healthcare Regulatory Authority 
(EuDRACT ref: 2008-002681-63) and the trial was prospectively registered with 
www.controlled-trials.com (ISRCTN63688695).All participants gave written informed 
consent, and the trial conformed to the principles of the Declaration of Helsinki. 
 
Intervention 
After completion of all baseline measurements including MRI if performed, participants were 
allocated the next sequentially numbered treatment pack. Packs contained either vitamin D3 
(Vigantol oil, donated by Merck Serono KgAA) or identical placebo oil (Mygliol oil, used as 
the base oil for Vigantol).  Medications were overlabelled and prepared by Tayside 
Pharmaceuticals (Dundee, UK) and were supplied in identical bottles with study number but 
no indication of group allocation. Allocation was therefore concealed from researchers and 
participants. After completion of assessments, a 5ml dose was administered by the study 
nurse at baseline, 2 months and 4 months to ensure 100% adherence. The total dose 
administered was therefore 300,000 units of vitamin D3 or placebo. All pre-study 
antihypertensive medications were continued. 
 
Outcome measures 
Outcomes were performed at 0, 2, 4 and 6 months by a research nurse blinded to study 
allocation. The primary outcome was between-group difference in mean 24 hour ambulatory 
systolic blood pressure at 6 months. 
 
24 hour blood pressure was measured using Meditech ABPM-04 ambulatory blood pressure 
monitors and analysed using Cardiovisions data analysis software. Blood pressure was 
measured a minimum of every 30 minutes during the day (0600 to 2200 hrs) and a minimum 
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of every 60 minutes overnight (2200 hrs to 0600 hrs). The mean of the total 24 hour readings 
was used as the primary outcome measure. Office blood pressure was measured in the supine 
position after 5 minutes of rest using an OMRON HEM-705CP automated blood pressure 
cuff. Three consecutive readings were taken; the mean of the second and third readings were 
taken as the outcome measure. Fasting blood was drawn for measuring 25-hydroxyvitamin D, 
which was measured using the IDS radioimmunoassay (coefficient of variation 6.3%). 
Calcium, parathyroid hormone (PTH), creatinine, glucose and total cholesterol were 
measured according to standard protocols in the Department of Biochemical Medicine, NHS 
Tayside, Dundee, UK. 
 
Echocardiography was performed at baseline on those participants willing and eligible to 
undertake the MRI substudy, using the method of Devereaux to estimate LV mass index16. 
Participants with left ventricular (LV) mass index of >110g/m2 (male) or >95g/m2 (female) 
were offered the opportunity to participate in the MRI substudy. 
 
Cardiac MRI 
Cardiac MRI was performed using a 3 Tesla Magnetom Trio scanner (Siemens, Erlangen, 
Germany). Following initial standard ‘localiser’ sequences, a series of 6mm short-axis (55 
degree flip angle) 2D segmented cine ECG-gated breath-hold steady state free precession 
(‘TrueFISP’) images were acquired from the base to apex of the left ventricle to enable 
measurement of LV mass and wall thicknesses. Post-processing delineation of epicardial and 
endocardial borders (at end-diastole and end-systole) was performed using commercial 
cardiac evaluation software (Argus VB17, Siemens) by an experienced MRI physicist who 
was blind to the treatment allocation and not otherwise involved with the running of the 
study.  Papillary muscles and trabeculae were routinely assigned to the LV blood pool if they 
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were identified as structurally distinct from the myocardial wall, but otherwise assigned to the 
myocardial mass.  Only those image slices that displayed greater than 50% full-thickness 
myocardium were analysed.  All datasets were evaluated twice over a time-course of one 
month in order to establish a mean (and corresponding repeatability evaluation) for the 
quantitative MRI parameters without the inclusion of segmentation learning effects. LV mass 
index was calculated by dividing LV mass by body surface area, calculated as the square root 
of ([weight in Kg x height in cm] / 3600). For measurement of left atrial end diastolic 
volume, 5mm multi-slice vertical long axis two chamber images were acquired from the 
lateral side of the left atrium to the atrial septum perpendicular to the plane of the mitral 
valve. The volume at atrial end-diastole contained by the atrial wall and the clearly delineated 
mitral valve was calculated. The left atrial appendage was included in the atrial volume 
measurements, and pulmonary vein structure was excluded wherever possible. 
 
Asymptomatic hypercalcaemia (>2.60 mmol/L) was recorded as a prespecified adverse 
outcome, and no further doses of study medication were administered if this occurred. All 
adverse events were recorded at each study visit along with information on medication use 
and comorbid disease. 
 
 
Statistical analysis 
The trial was powered for an 8 mmHg fall in systolic blood pressure, based on data from 
previous trials using similar doses of vitamin D17;18. Assuming a standard deviation of change 
of 11mmHg, 31 patients per group (62 in total) would be required to detect this change with 
80% power at alpha=0.05.  To achieve this final evaluable sample size of 62 participants, we 
originally aimed to recruit a total of 74 patients to allow for a dropout rate of 20%, based on 
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previous similar studies in our department. For LV mass index, a change of 10 grams is 
regarded as clinically significant, and a total of 26 to 30 subjects is required to demonstrate a 
10 gram change with 90% power at alpha=0.0519. 
 
Analyses were performed using SPSS version 18 (SPSS, Chicago, USA). Comparisons 
between continuous variables were performed using analysis of variance (ANOVA) at each 
timepoint. Categorical variables were compared using Pearson’s chi-squared, or using 
Fisher’s exact test when the contents of any cell was 5 or less. Repeated measures ANOVA 
was also undertaken to estimate the overall treatment effect using all available data for 
outcomes with more than two timepoints; for cardiac MRI, ANOVA was used to compare six 
month values between groups, adjusting for baseline values. Multiple imputation was used to 
address missing data for the primary outcome; 5 imputations were performed, using baseline 
and follow up blood pressure data, baseline age, sex and 25OHD level to generate imputed 
datasets. A sensitivity analysis was performed, excluding participants who changed their 
antihypertensive medication over the 6 month study period. A 2-sided p value of 0.05 was 
taken as significant for all analyses. 
 
 
Results 
Details of participant flow through the trial are given in Figure 1. 68 participants met the 
inclusion and exclusion criteria and were randomised into the study. Randomisation took 
place between January 2009 and February 2011. Baseline details for the 68 subjects 
randomised into the trial are shown in Table 1. All participants were of Caucasian ethnic 
background. 61/68 (90%) of participants underwent the 6 month visit. Recruitment was 
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terminated before the target number of participants was reached due in part to slow 
recruitment rates and in part due to the lower than anticipated dropout rate. 
 
Table 2 shows the effect of the intervention on the 24 hour blood pressure and office blood 
pressure. No significant improvement in either 24 hour blood pressure or office blood 
pressure was seen with vitamin D supplementation at any timepoint; indeed the repeated 
measures analysis suggested a non-significant increase in blood pressure in the treatment 
group. Sensitivity analysis was performed using multiple imputation to address missing data 
for the primary outcome. The treatment effect for 24 hour ambulatory systolic blood pressure 
remained non-significant (+1mmHg, 95% CI -3 to +5), and the effect for 24 hour ambulatory 
diastolic blood pressure was of borderline significance (-3mmHg, 95% CI -6 to 0). A further 
sensitivity analysis was performed excluding the 9 participants (4 in vitamin D group, 5 in 
placebo group) who changed antihypertensive medication during the trial. In this analysis, 
little difference was seen in the results for 24 hour blood pressure (repeated measures systolic 
treatment effect 3mmHg, 95%CI -4 to 11, p=0.38; diastolic treatment effect 2mmHg, 95%CI 
-6 to 9, p=0.67) or for office blood pressure (repeated measures systolic treatment effect 
3mmHg, 95%CI -4 to 10, p=0.38; diastolic treatment effect -3mmHg, 95%CI -8 to 2, p=0.30) 
 
Adjusted repeated measures analysis of daytime ambulatory blood pressure change showed 
no effect of vitamin D (systolic treatment effect +1 mmHg, 95%CI -6 to 9; diastolic treatment 
effect -3mmHg, 95% CI -7 to +1); similarly, analysis of night-time ambulatory blood 
pressure change showed no significant treatment effect (systolic treatment effect +4 mmHg, 
95%CI -3 to +12; diastolic treatment effect -1mmHg, 95% CI -6 to +3) 
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Table 3 shows the results of the cardiac MRI substudy. 37 patients progressed to MRI 
scanning at baseline; eight participants did not complete baseline MRI scans successfully, 
due to breathlessness (two participants), claustrophobia (three participants) and failure to fit 
into the scanner (three participants). A total of 29 patients therefore underwent successful 
baseline MRI scanning; 25 underwent follow-up scans at 6 months (11 in the treatment arm, 
14 in the placebo arm). Left atrial images of sufficient quality for volumetric analysis at both 
baseline and follow up were available for 15 participants. Baseline end-diastolic volume and 
LV mass index were non-significantly lower in the vitamin D group. No difference in 
ejection fraction, left ventricular end-diastolic volume or left atrial end-diastolic volume was 
seen with treatment; LV mass index increased slightly with treatment, with this change 
reaching significance after adjustment for baseline blood pressure and 25OHD level. 
 
Similar numbers of adverse events were noted in each group; 35 in the active treatment arm 
and 38 in the placebo group. No participant died during trial participation; one participant 
suffered a cardiovascular event in the active treatment group (angina) not requiring 
hospitalisation, and one suffered a cardiovascular event in the placebo group (myocardial 
infarction) requiring hospitalisation. No participant had serum calcium >2.60mmol/L at any 
timepoint. Details of adverse events are given in Supplementary Table 1 
 
 
Discussion 
This study failed to show any effect of high-dose, intermittent vitamin D supplementation on 
blood pressure, cholesterol, glucose or LV mass measured using cardiac MRI. This was 
despite the administration of relatively high doses of oral vitamin D (equivalent to 1800 
units/day), with a substantial and sustained rise in 25OHD levels in the treatment group. 
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Several possibilities merit discussion to explain our findings. It is possible that the dose of 
vitamin D was insufficient to produce the required biological effect. Previous studies using 
similar doses in selected patients groups (e.g. those with type 2 diabetes) have however 
shown significant reductions in blood pressure; these studies included a proportion of patients 
with suboptimally treated hypertension17;18. Although the 25OHD levels fell short of the 
75nmol/L level claimed by some commentators to be necessary for optimum health20, no 
evidence exists to support a threshold effect of 25OHD level to produce beneficial vascular 
effects. Similarly, although the study was only of 6 months duration, reductions in blood 
pressure in previous studies have been seen within a few weeks of large oral doses of vitamin 
D. Reduction in LV mass on MRI has been demonstrated within 9 months with other vascular 
interventions, for instance by previous studies on allopurinol and on blood pressure 
reduction21;22. Our results are however consistent with the main findings of  the PRIMO trial, 
which showed no effect of 48 weeks of paricalcitol therapy on LV mass in patients with 
advanced kidney disease14. Changes in left atrial volume may provide a more sensitive early 
measure of cardiac remodelling, and a substudy of PRIMO did find a reduction in left atrial 
volume with paricalcitol therapy23; we were unable to demonstrate this in the current study 
although the number of patients with usable left atrial volumetric information was low. 
 
Another possibility is that only selected groups of patients at risk of vascular disease benefit 
from vitamin D supplementation. The effect of vitamin D on blood pressure in a previous 
meta-analysis was seen only in those studies where blood pressure was elevated at baseline11 
and patients with type 2 diabetes mellitus appeared to benefit more in terms of blood pressure 
reduction. Participants in the current study were all hypertensive at baseline, but few had 
diabetes. Participants were taking a wide range of antihypertensive agents, thus many of the 
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available biological pathways for blood pressure reduction may have already been engaged. 
Vitamin D has been posited to exert antihypertensive effects via effects on the renin-
angiotensin-aldosterone system, either by direct inhibition of renin24, or by angiotensin 
converting enzyme (ACE) inhibitor-like effects25. A high percentage of participants were 
taking ACE inhibitors, angiotensin receptor blockers and/or aldosterone antagonists; this may 
have served to obviate any further benefit of adding vitamin D. Another possibility is that 
those with different ethnic or genetic backgrounds may respond differently; a recent trial in 
black Americans showed a reduction in blood pressure with vitamin D; higher doses of 
vitamin D produced larger falls in blood pressure26. The lack of effect seen in this study does 
not exclude an effect in non-resistant or drug-naive hypertensive patients; such patients may 
still respond to manipulation of biological pathways by vitamin D that do not respond, or 
have already been utilised, in treated, resistant hypertensive patients. 
 
Strengths of our study include the randomised, blinded design, the use of 24 hour blood 
pressure measurements, and the assessment of LV mass index – a key independent marker of 
vascular events and vascular death. Limitations include the relatively small study size, 
Caucasian study population, lack of follow-up beyond 6 months, and the obscuring effect of 
multiple treatments; an inevitable limitation when studying patients with resistant 
hypertension.  
 
Perspectives 
High-dose intermittent oral vitamin D3 therapy did not reduce blood pressure or LV mass in 
patients with resistant hypertension on multiple antihypertensive agents. Further research 
could focus on whether larger doses of vitamin D given for longer might be more effective, 
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or whether prespecified subgroups (e.g. those with diabetes or not taking renin-angiotensin 
system blockers) might still show reductions in blood pressure with vitamin D. 
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Novelty and Significance: 
1) What is new? 
- Trials of vitamin D supplementation to date have not focussed on patients with 
resistant hypertension; this placebo-controlled trial is the first to do so. There was 
no reduction in blood pressure or left ventricular hypertrophy after six months of 
high-dose, intermittent oral vitamin D3 supplementation 
2) What is the significance? 
- Although observational data suggest a link between low vitamin D levels and 
higher blood pressure, trial results to date have been inconsistent. These results do 
not support the use of vitamin D as a therapy for this difficult to treat group of 
patients. 
3) Summary: 
- This dose and duration of vitamin D was not effective at reducing blood pressure 
or left ventricular mass in this population of patients with resistant hypertension. 
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Figure legends: 
 
Fig 1. Participant flow through trial 
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Table 1. Baseline details of randomised participants 
 
Parameter Active 
(n=34) 
Placebo 
(n=34) 
P 
Age (years) (SD) 65.1 (9.4) 61.4 (12.7) 0.18 
Male Sex (%) 22 (65) 22 (65) 1.0 
Mean office systolic blood pressure (mmHg) (SD) 153 (11) 155 (14) 0.51 
Mean office diastolic blood pressure (mmHg) (SD) 82 (10) 86 (9) 0.06 
Mean 24 hr systolic blood pressure (mmHg) (SD) 138 (18) 137 (13) 0.76 
Mean 24 hr diastolic blood pressure (mmHg) (SD) 76 (8) 78 (9) 0.38 
Mean daytime systolic blood pressure (mmHg) (SD) 142 (18) 140 (13) 0.72 
Mean daytime diastolic blood pressure (mmHg) (SD) 78 (9) 81 (9) 0.16 
Mean nighttime systolic blood pressure (mmHg) (SD) 134 (20 128 (16) 0.18 
Mean nighttime diastolic blood pressure (mmHg) (SD) 71 (8) 73 (10) 0.53 
Previous myocardial infarction (%) 5 (15) 3 (9) 0.48 
Angina (%) 7 (21) 5 (15) 0.54 
Peripheral vascular disease (%) 1 (3) 0 (0) 1.0 
Stroke / TIA (%) 3 (9) 4 (12) 0.26 
Diabetes mellitus (%) 9 (27) 8 (24) 1.0 
Current smoker (%) 3 (9) 1 (3) 0.61 
BMI (Kgm-2) (SD) 31.4 (5.3) 32.0 (5.5) 0.61 
LV mass index by echocardiography (gm-2) (SD) 140 (40) 140 (23) 0.97 
Median number of antihypertensives (IQR) 3.5 (2) 3 (1) 0.54 
On ACE inhibitor (%) 14 (42) 17 (50) 0.47 
On ARB (%) 17 (50) 17 (50) 1.0 
On alpha blocker (%) 19 (54) 12 (35) 0.09 
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On beta blocker (%) 13 (38) 14 (42) 0.80 
On calcium channel blocker (%) 22 (65) 28 (84) 0.10 
On thiazide (%) 20 (59) 17 (50) 0.47 
On aldosterone antagonist (%) 8 (24) 11 (32) 0.42 
On any diuretic (%) 29 (85) 30 (88) 0.72 
25OHD (nmol/L) (SD) 41 (14) 42 (18) 0.85 
Adjusted calcium (mmol/L) (SD) 2.29 (0.08) 2.32 (0.06) 0.10 
PTH (pmol/L) (SD) 5.6 (2.7) 5.2 (2.2) 0.44 
Glucose (mmol/L) (SD) 6.8 (3.0) 6.1 (2.0) 0.31 
Cholesterol (mmol/L) (SD) 4.6 (0.8) 4.6 (1.1) 0.90 
 
TIA: Transient ischaemic attack 
BMI: Body mass index 
LV: Left ventricular 
ACEi: Angiotensin converting enzyme inhibitor 
ARB: Angiotensin receptor blocker 
25OHD: 25-hydroxyvitamin D 
PTH: Parathyroid hormone  
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Table 2. Effect of vitamin D supplementation on mean 24 hour ambulatory blood 
pressure and office blood pressure 
 
24 hour ambulatory blood pressure 
Timepoint Vitamin D Placebo P Vitamin D Placebo P 
Systolic BP (mmHg)(SD) Diastolic BP (mmHg)(SD) 
Baseline 138 (18) 137 (13) 0.76 76 (8) 78 (9) 0.38 
2 mths 136 (15) 134 (13) 0.55 75 (8) 79 (9) 0.09 
4 mths 137 (17) 130 (9) 0.25 73 (8) 79 (10) 0.10 
6 mths 136 (14) 130 (14) 0.12 76 (8) 78 (9) 0.28 
Unadjusted 
RM* 
4 (-3 to 11) 0.20 -2 (-6 to 2) 0.29 
Adjusted RM* 
† 
3 (-4 to 11) 0.33 -2 (-7 to 2) 0.26 
     
Office blood pressure 
 Vitamin D Placebo P Vitamin D Placebo P 
Systolic BP (mmHg)(SD) Diastolic BP (mmHg)(SD) 
Baseline 153 (11) 155 (14) 0.51 82 (10) 86 (9) 0.06 
2 mths 154 (18) 150 (12) 0.40 82 (10) 83 (11) 0.66 
4 mths 152 (14) 147 (13) 0.21 81 (11) 82 (10) 0.64 
6 mths 151 (19) 146 (16) 0.35 82 (8) 80 (11) 0.40 
Unadjusted 
RM* 
4 (-2 to 10) 0.24 -3 (-7 to 1) 0.18 
Adjusted RM* 4 (-3 to 10) 0.25 -3 (-7 to 1) 0.18 
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† 
 
*Repeated measures treatment effect. †Adjusted for baseline 25OHD level 
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Table 3: Cardiac MRI measures 
 
Timepoint Active (n=11) Placebo (n=14) p 
Baseline EF (%) (SD)  72.3 (6.0) 71.5 (6.5) 0.74 
6 month EF (%) (SD) 70.6 (3.7) 70.0 (8.1) 0.79 
Unadjusted treatment effect (95% CI) 0.2 (-4.7 to 5.2) 0.92 
Adjusted* treatment effect (95% CI) 2.0 (-3.1 to 7.1) 0.43 
    
Baseline LVMI (gm-2) (SD) 57 (13) 62 (16) 0.58 
6 month LVMI (gm-2) (SD) 58 (13) 61 (16) 0.58 
Unadjusted treatment effect (95% CI) 2 (-1 to 5) 0.26 
Adjusted* treatment effect (95% CI) 4 (0 to 7) 0.04 
    
Baseline LVEDV (cm3) (SD) 140 (32) 155 (26) 0.21 
6 month LVEDV (cm3) (SD) 136 (26) 154 (41) 0.22 
Unadjusted treatment effect (95% CI) -3 (-22 to 16) 0.73 
Adjusted* treatment effect (95% CI) -8 (-29 to 13) 0.45 
 n=7 n=8  
Baseline LAEDV (cm3) (SD) 116 (41) 88 (16) 0.10 
6 month LAEDV (cm3) (SD) 113 (35) 95 (15) 0.22 
Unadjusted treatment effect (95% CI) -3 (-20 to 13) 0.67 
Adjusted* treatment effect (95% CI) -3 (-30 to 22) 0.77 
 
*adjusted for baseline systolic BP and 25OHD level 
EF: Ejection fraction 
LVMI: Left ventricular mass index 
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LVEDV: Left ventricular end diastolic volume 
LAEDV: Left atrial end diastolic volume
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Table 4. Metabolic outcomes 
Parameter Repeated measures treatment effect 
(95% CI) 
p 
25OHD (nmol/L) 22 (17 to 28) <0.001 
Adjusted calcium (mmol/L) -0.01 (-0.04 to 0.02) 0.54 
PTH (pmol/L) -0.8 (-1.5 to 0.0) 0.05 
Fasting glucose 0.0 (-0.8 to 0.8) 0.99 
Total cholesterol 0.1 (-0.2 to 0.3) 0.57 
 
25OHD: 25-hydroxyvitamin D 
PTH: Parathyroid hormone 
 
